A series of successful phase two clinical trials and increasing commercial adoption in the US market for Aussie biotech companies have driven the creation of three new billion-dollar healthcare stocks in just a few months.
In the past six months more than $3.25 billion dollars has been added to the valuations of a handful of small and mid cap healthcare stocks like Avita Medical, Opthea, PolyNovo and Paradigm Biopharmaceuticals.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
